Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Loïc Renaud, Jean‐Baptiste Bossard, Benjamin Carpentier, Louis Terriou, Nathalie Cambier, Guillaume Chanteau, Guillaume Escure, Rémi Tilmont, Sarah Barbieux, Mathieu Wémeau, Julia Hieulle, Eileen M. Boyle, Franck Morschhauser
Abstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Topics & Concepts
IbrutinibTemozolomideRefractory (planetary science)GlioblastomaLymphomaMedicinePrimary (astronomy)OncologyPrimary central nervous system lymphomaInternal medicineComputer scienceCancer researchLeukemiaAstrobiologyChronic lymphocytic leukemiaAstronomyPhysicsCNS Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment